Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Galardi

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Cancers|June 2, 2021
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast CancerIlenia Migliaccio, Angela Leo, Francesca Galardi, et al.
Molecular Oncology|December 26, 2014
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patientsMarta Pestrin, Francesca Salvianti, Francesca Galardi, et al.
Biomolecular Detection and Quantification|April 15, 2016
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencingFrancesca Salvianti, Giada Rotunno, Francesca Galardi, et al.
Breast Cancer Research and Treatment|July 15, 2009
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsMarta Pestrin, Silvia Bessi, Francesca Galardi, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
Biomolecules|December 18, 2020
Cell-Free DNA-Methylation-Based Methods and Applications in OncologyFrancesca Galardi, Francesca De Luca, Dario Romagnoli, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Breast (Edinburgh, Scotland)|March 13, 2012
Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patientsFrancesca Galardi, Catherine Oakman, Maria Caterina Truglia, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Oncotarget|April 2, 2016
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancerFrancesca De Luca, Giada Rotunno, Francesca Salvianti, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Cancers|June 2, 2021
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast CancerIlenia Migliaccio, Angela Leo, Francesca Galardi, et al.
Molecular Oncology|December 26, 2014
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patientsMarta Pestrin, Francesca Salvianti, Francesca Galardi, et al.
Biomolecular Detection and Quantification|April 15, 2016
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencingFrancesca Salvianti, Giada Rotunno, Francesca Galardi, et al.
Breast Cancer Research and Treatment|July 15, 2009
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsMarta Pestrin, Silvia Bessi, Francesca Galardi, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
Biomolecules|December 18, 2020
Cell-Free DNA-Methylation-Based Methods and Applications in OncologyFrancesca Galardi, Francesca De Luca, Dario Romagnoli, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Breast (Edinburgh, Scotland)|March 13, 2012
Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patientsFrancesca Galardi, Catherine Oakman, Maria Caterina Truglia, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Oncotarget|April 2, 2016
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancerFrancesca De Luca, Giada Rotunno, Francesca Salvianti, et al.
Pageof 4